<DOC>
	<DOCNO>NCT00439621</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy three dose two dosing regimen RP01 anti-IgE immunotherapy allergic patient .</brief_summary>
	<brief_title>Safety Study Anti-IgE Immunotherapy Allergic Patients</brief_title>
	<detailed_description>Immunotherapy base principle elicit immune reaction order block negative effect specific disease-causing protein . The potential treat disease mean immunotherapy instead use conventional drug represent attractive opportunity number chronic disease area , include asthma allergy . Resistentia 's model treat allergic disease , ultimately asthma , use immune system produce antibody IgE molecule . The result anti-IgE antibody intercept form complex IgE molecule bind mast cell basophils thus able block allergen-triggered inflammatory reaction . The approach work type IgE-mediated allergy independently allergen , also patient sensitive multiple allergen . Comparisons : Three dos two dose regime RP01 compare regard safety effect .</detailed_description>
	<criteria>Allergy least one aero allergen Increased serum IgE level Diagnosis asthma Recent use systemic corticosteroid immunosuppressive treatment Allergy vaccination therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>allergy</keyword>
</DOC>